Survodutide
BI 456906 / EX-A7878 (Boehringer Ingelheim; originally co-developed with Zealand Pharma)
The Ground Truth Score
four plain questions, never one numberReal Phase 2/3 evidence, no approval yet, barely on the grey market
Bottom line
Survodutide is a genuinely promising glucagon/GLP-1 dual agonist with strong randomized human data for weight loss and MASH, but it is still investigational, not FDA-approved, and almost absent from the research-peptide community, so real-world anecdote is thin.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
InvestigationalIn trials, not availableIn company-sponsored clinical trials with a real sponsor and real data, but not approved and not compoundable. Anything sold under this name outside a trial is not the trial drug, has not been through that sponsor's manufacturing, and has never been tested as sold.
Boehringer Ingelheim's glucagon/GLP-1 dual agonist, Phase 3 (SYNCHRONIZE). Not approved. Same caveat as retatrutide.
Legal status as of 2026-06-08. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Investigational dosing (from trials, NOT a prescription): once-weekly subcutaneous injection with stepwise uptitration.
Reported, not prescribed. Verify your vial and your math.
First documented human use
Phase 1 first-in-human single/multiple-rising-dose studies in healthy volunteers and people with overweight/obesity were conducted in Germany and Japan (program initiated ~2018-2019; PK/safety reported thereafter). It has NEVER been approved for marketing, as of June 2026 it remains investigational and available to humans only through Boehringer Ingelheim's clinical trials.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- Dual agonist: GLP-1 arm curbs appetite/raises satiety while the glucagon arm raises energy expenditure and drives hepatic fat oxidation, the glucagon component is the differentiator vs semaglutide.
- Phase 2 obesity (Lancet Diab Endocrinol 2024): up to ~19% mean body-weight reduction at 46 weeks on 4.8 mg weekly, with up to ~40% of high-dose patients losing >=20%.
- Phase 2 MASH (NEJM, June 2024): MASH improvement without fibrosis worsening in up to 62% (4.8 mg) vs 14% placebo at 48 weeks; earned FDA Breakthrough Therapy designation (Oct 2024).
- Phase 3 SYNCHRONIZE-1 topline (Nov 2025): 16.6% mean weight loss at 76 weeks vs 3.2% placebo, mostly fat mass. SYNCHRONIZE-MASLD published in Nature Medicine (June 2026).
The data behind each bullet
What actually backs it
In the Phase 2 obesity dose-finding trial, survodutide 4.8 mg once-weekly produced up to ~19% mean body-weight reduction at 46 weeks (published Lancet Diabetes & Endocrinology, 2024).
Single randomized, double-blind, placebo-controlled Phase 2 dose-finding RCT in overweight/obesity without diabetes.
PubMed: survodutide obesity phase 2 (Lancet Diab Endocrinol 2024) ↗In the Phase 2 MASH trial, MASH improvement without worsening of fibrosis occurred in 47% (2.4 mg), 62% (4.8 mg) and 43% (6.0 mg) of survodutide groups vs 14% placebo at 48 weeks (NEJM, June 2024).
295-patient randomized, double-blind, placebo-controlled Phase 2 dose-finding RCT, biopsy-confirmed MASH F1-F3, published NEJM.
PubMed: survodutide MASH phase 2 randomized trial (NEJM 2024) ↗Phase 3 SYNCHRONIZE-1 reported 16.6% mean body-weight reduction at 76 weeks vs 3.2% placebo in adults with obesity/overweight without type 2 diabetes (topline Nov 2025).
Topline/company-announced Phase 3 RCT result; baseline-characteristics and design papers indexed, full primary results emerging in 2026.
ClinicalTrials.gov: SYNCHRONIZE-1 (NCT06066515) ↗Survodutide received FDA Breakthrough Therapy designation for noncirrhotic MASH with moderate/advanced (F2-F3) fibrosis in October 2024; it is NOT FDA-approved for any indication.
Regulatory designation (Breakthrough Therapy is not an approval); confirmed via FDA/company announcement and pivotal LIVERAGE Phase 3 still ongoing.
ClinicalTrials.gov: LIVERAGE Phase 3 MASH (NCT06632444) ↗GI adverse events (nausea/vomiting/diarrhea), concentrated during rapid dose escalation, drove discontinuation of ~24.6% on survodutide vs 3.9% placebo in the Phase 2 obesity trial; a mean heart-rate rise of ~2.7 bpm was seen (similar to semaglutide ~3 bpm).
Pre-specified safety data from the Phase 2 obesity RCT; discontinuation rate is escalation-schedule-dependent and may fall with slower titration.
ClinicalTrials.gov: SYNCHRONIZE-CVOT cardiovascular safety (NCT06077864) ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
Yes — weight/waist plus DEXA fat-mass/VAT are direct efficacy readouts, and liver-fat imaging (FibroScan CAP or MRI-PDFF) directly tracks the MASH arm; all three are now backed by human Phase 2/3 data.
Bloodwork
A lab moves, but it's noisy, indirect, or off-target — treat it as a hint, not proof.
Survodutide is a dual glucagon-receptor (GCGR) + GLP-1-receptor agonist (BI 456906) with positive phase 2 human data in obesity (Lancet Diabetes Endocrinol 2024) and MASH (NEJM 2024). Its systemic metabolic action does surface in routine bloodwork, but every blood signal is an INDIRECT proxy: the registrational efficacy readouts are bodyweight/waist for obesity and liver MRI-PDFF/histology for MASH, not a lab value. So bloodwork can show the drug is producing real metabolic action, but no routine lab is a clean efficacy endpoint.
In a user with baseline-elevated transaminases from hepatic steatosis, ALT (and AST) trending toward or into the normal range. Do NOT read a fall as drug-specific: generic weight loss lowers ALT too, and the trial's real endpoint was liver fat/histology, not enzymes.
Glucagon-receptor agonism drives hepatic fat oxidation and reduced steatosis; ALT fell in the MASH RCT. Most survodutide-relevant blood signal, but non-specific and cannot separate drug effect from weight-loss effect.
Only meaningfully informative if baseline is prediabetic/diabetic, where a modest downward trend can appear. In a normoglycemic user expect little to no movement; a flat HbA1c does NOT mean the drug is failing, since weight loss (not glycemia) is the efficacy readout in obesity.
The GLP-1 arm augments glucose-dependent insulin secretion, but the counter-regulatory glucagon arm blunts glycemic lowering versus a pure GLP-1 agonist, so the signal is small and only useful off an elevated baseline.
Draw baseline
Before first dose, before dose-escalation begins
Retest
~12 weeks, after the slow titration reaches maintenance dose; liver enzymes may keep drifting down out to ~24 weeks
Read this before you spend on labs
Bloodwork is a supporting readout for survodutide, not proof of efficacy. The cleanest evidence it is working is the scale and tape measure (obesity) or liver imaging/histology (MASH) — not labs. The two lab signals kept here are both indirect and confounded: ALT/AST fall in steatosis but generic weight loss lowers them too, and HbA1c barely moves in a non-diabetic because the glucagon arm counter-regulates the GLP-1 glycemic effect. Treat a flat panel as uninformative, not as failure.
- le Roux CW et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (Lancet Diabetes Endocrinol 2024) PMID 38330987 ↗
- Sanyal AJ et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (NEJM 2024) PMID 38847460 ↗
Other ways to track it
Home scale + tape measure (waist circumference) + BP cuff — body weight, waist, resting blood pressure and heart rate
A working response shows steady weight loss and a shrinking waist over weeks to months — weight is survodutide's registrational primary endpoint (Phase 2 obesity averaged ~19% at 46 wks; Phase 3 SYNCHRONIZE-1 16.6% at 76 wks vs 3.2% placebo). BP often drifts down with fat loss. Honest counter-signal to watch: resting HR tends to tick UP on incretin agents, so a rising pulse is a side-effect flag, not efficacy.
The GLP-1 arm suppresses appetite and the glucagon arm raises energy expenditure — the resulting caloric deficit shows up first and most reliably on the scale and tape.
DEXA scan — total/regional fat mass, visceral adipose tissue (VAT), and lean/appendicular mass
Working = fat mass and VAT fall while lean mass is largely preserved. This is validated in humans for the compound: the SYNCHRONIZE-1 body-composition sub-study showed VAT down up to ~34% at 76 wks, with lean-mass loss limited to ~10.8% of total tissue-mass change. The load-bearing reason to scan rather than just weigh: DEXA separates the good loss (fat/VAT) from the bad (lean muscle), which rapid incretin-driven weight loss can also strip.
Confirms at scan level that the weight coming off is adipose (specifically visceral fat, the metabolically dangerous depot) and acts as the guardrail against excessive lean-mass loss.
Liver-fat imaging — FibroScan (VCTE): CAP for steatosis + kPa for stiffness/fibrosis; MRI-PDFF liver-fat fraction if orderable (the trial gold standard)
This is the objective readout that distinguishes survodutide from pure GLP-1s. For the MASH use, liver fat drops — the Phase 2 MASH trial used MRI-PDFF, with 67% of the 4.8 mg group achieving a >=30% liver-fat reduction (vs 14% placebo), and the SYNCHRONIZE-1 sub-study showed liver fat down up to ~63% at 76 wks. FibroScan CAP is the accessible clinic proxy for steatosis and moves within months; kPa (fibrosis) improves more slowly and is a longer-horizon read. Blood already covers ALT/AST (partial); imaging is the direct structural complement.
Glucagon-receptor agonism drives hepatic fat oxidation while the GLP-1 arm curbs lipogenesis, so liver-fat content is a direct, imaging-verifiable efficacy target — not merely a downstream of body weight.
Bottom line
Survodutide is unusually trackable for a peptide because it has two objective efficacy axes with accessible readouts: fat loss (scale/waist + DEXA fat-mass and VAT) and hepatic fat clearance (FibroScan CAP or MRI-PDFF for the MASH indication), both now backed by human Phase 3 body-composition and Phase 2 MASH imaging data. Honest caveats: it's investigational (FDA Breakthrough Therapy for MASH, Oct 2024; not approved), so this is off-label use; DEXA and liver imaging need clinic access and 4-6 month windows to read cleanly; and none of these readouts separate the drug's effect from the caloric deficit it drives. CGM was dropped from this panel — the glucagon arm actively opposes glucose lowering, so any CGM signal is confounded and redundant with weight, not a clean efficacy proxy. Watch two side-effect signals that are NOT efficacy: lean-mass loss on DEXA and a rising resting heart rate.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Confirmed (not merely assumed) by extensive human PK/PD and biopsy-endpoint trials: a synthetic ~29-residue peptide that is a glucagon analog (not an oxyntomodulin analog) acting as a balanced dual agonist at the GLP-1 receptor and the glucagon receptor. GLP-1 agonism suppresses appetite and increases satiety (acting via brain circumventricular organs/appetite centers and slowing gastric emptying); glucagon agonism increases energy expenditure and acts directly on the liver to drive lipolysis/fat oxidation, reducing hepatic fat and improving steatohepatitis/fibrosis markers. It is albumin-bound via a C18 diacid for half-life extension.
Dosing & handling
What users and clinicians report
Investigational dosing (from trials, NOT a prescription): once-weekly subcutaneous injection with stepwise uptitration. Phase 2 obesity used escalation to maintenance doses of 2.4, 3.6, 4.8 mg weekly (and 6.0 mg in MASH); ~4.8 mg/week was the efficacy sweet spot for weight loss, ~4.8 mg for MASH. Escalation in trials was relatively rapid (steps every ~2 weeks), which is itself implicated in the high GI-driven dropout.
These are clinical-trial regimens reported for context only, not a protocol to self-administer. The drug is unapproved and not legally sold through compounding pharmacies; there is no validated consumer product, so reconstitution/dose figures from trials cannot be safely mapped onto grey-market powder of unknown content. GI tolerability and the modest heart-rate rise mean any dosing should be physician-supervised.
Timing & food
In trials, dosed once weekly on a fixed day, subcutaneously, and, like other GLP-1-class agents, it can be taken without regard to meals (food timing does not gate absorption of a long-acting albumin-bound peptide). The week-by-week uptitration exists specifically to let GI tolerance adapt; the rationale for slow escalation is to blunt the nausea/vomiting that otherwise drives discontinuation during the first weeks.
Half-life
Extended terminal half-life of approximately 109-115 hours (~4.5-5 days), supporting once-weekly subcutaneous dosing; high (>99%) human serum albumin binding via a C18 diacid linker drives the prolonged exposure. Steady state is reached by roughly week 5 of weekly dosing.
Reconstitution sensitivity
No data exists for grey-market handling because there is no legitimate consumer product, clinical supply is a manufacturer-formulated injectable. By analogy to other albumin-binding GLP-1-class peptides, a lyophilized powder would be expected to need reconstitution with bacteriostatic water, refrigeration once reconstituted, and protection from heat, agitation and light; any such handling of an unapproved compound is outside validated guidance and carries identity/purity risk.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Low for real user experience. Public discussion volume is high in aggregate but is overwhelmingly pharma news, analyst coverage and clinician commentary on trial readouts, not first-hand self-administration reports. Unlike retatrutide, survodutide barely appears among research-peptide vendors or in forum dosing threads, so genuine community-use volume is faint.
Consistency
Within the clinical/news sphere, sentiment is consistent and positive (strong weight-loss and MASH signals, breakthrough designation). What little real-world chatter exists is fragmentary and inconsistent, often conflated with other dual/triple agonists, so there is no coherent body of reproducible anecdote to weigh.
Source credibility
The credible signal is the clinical-trial evidence itself (high credibility: NEJM, Lancet, Nature Medicine, registered RCTs). Community/anecdotal credibility is low-to-nonexistent: any 'survodutide' sold grey-market is unverified and may be mislabeled, and biohacker reports are sparse and heavily confounded. Affiliate/telehealth blog content promoting it should be discounted, the drug is not legally dispensable.
- Clinical-trial participants and the medical community frame it as a high-efficacy 'next-wave' obesity/MASH agent, excitement centers on weight loss approaching the tirzepatide/retatrutide tier plus a genuine liver-fibrosis benefit, not on lived consumer experience.
- The dominant practical caveat echoed by clinicians is tolerability: GI side effects during the fast titration are the main reason people drop out, with broad agreement that slower dose-escalation should improve real-world adherence.
- In biohacker/peptide circles the recurring theme is availability frustration, survodutide is repeatedly noted as NOT readily obtainable from research-peptide vendors (in sharp contrast to retatrutide), so hands-on self-report is scarce and people often default to the more accessible compounds.
- Where the compound is discussed by self-experimenters, sentiment is cautious and skeptical about grey-market sourcing/mislabeling, with awareness that 'survodutide' powder of unknown origin cannot be trusted and that the cleaner path is a clinical trial or waiting for approval.
Placebo risk, Low
Placebo risk is rated Low because the headline endpoints are objective and instrument-measured, not subjective: body weight on a scale, body composition (fat mass), waist circumference, liver-fat fraction by MRI-PDFF, HbA1c, and biopsy-graded MASH activity and fibrosis stage. Effects were demonstrated against placebo arms in double-blind RCTs with large between-group separations, which is the opposite of a placebo-driven result. (Subjective appetite suppression is real but is corroborated by the objective weight change.)
Risk panel
What could go wrong
Adverse events
Gastrointestinal events dominate, nausea, vomiting, diarrhea, decreased appetite, mostly mild-to-moderate and clustered during the rapid (every-2-week) dose-escalation phase. In Phase 2 obesity, GI events drove a ~24.6% discontinuation rate (vs 3.9% placebo). A modest resting heart-rate increase (~2.7 bpm mean) was observed, consistent with the GLP-1 class. Serious adverse events were actually numerically lower on drug (4.2%) than placebo (6.5%) in that trial.
Theoretical concerns
As a GLP-1 receptor agonist, it carries the class-wide theoretical concerns: rodent C-cell/medullary thyroid tumor signal (basis of the class boxed warning for approved GLP-1 drugs, contraindicated with personal/family history of MTC or MEN2), pancreatitis, gallbladder events, and possible worsening of diabetic retinopathy. The glucagon arm adds a theoretical concern for raising glucose/hepatic glucose output and heart rate, which is why glycemic control and cardiovascular safety (SYNCHRONIZE-CVOT) are being formally studied.
Contraindications
Not an approved drug, so no formal labeled contraindications exist yet. By GLP-1 class analogy, would be expected to be contraindicated/cautioned in personal or family history of medullary thyroid carcinoma or MEN2, prior pancreatitis, severe GI/gastroparesis, and pregnancy/breastfeeding. The glucagon component warrants extra caution in poorly controlled diabetes and significant cardiovascular disease.
Honest unknowns
Long-term (multi-year) safety, durability of weight/fibrosis benefit after stopping, and cardiovascular outcomes are not yet established (CVOT ongoing). The optimal titration schedule to minimize GI dropout is still being refined. Critically for self-experimenters: there is essentially no quality-controlled grey-market supply, so any non-trial product carries unverified identity, purity, dose-accuracy and sterility risk on top of the drug's own unknowns.
Confound watch
Trial weight/metabolic results are confounded by intensive lifestyle/diet co-intervention and structured titration baked into the protocols. The glucagon arm's metabolic-rate contribution is hard to separate from appetite-driven calorie reduction. Any anecdotal report is additionally confounded because the same users typically stack other GLP-1s/peptides, and mislabeled grey-market 'survodutide' may actually be semaglutide/tirzepatide/retatrutide, so attributing effects to survodutide specifically is unreliable.
History
Discovery → first use → status
- ~2018-2019First-in-human Phase 1 single/multiple-rising-dose studies (healthy volunteers and overweight/obese) conducted in Germany and Japan; co-developed by Boehringer Ingelheim and Zealand Pharma.
- 2023 (Jun)Phase 2 obesity topline reported nearly 19% weight loss; data presented at ADA / via press.
- 2023 (Nov)Accepted into the EMA PRIME scheme for MASH.
- 2024 (Feb)Phase 2 obesity dose-finding RCT published in The Lancet Diabetes & Endocrinology.
- 2024 (Jun)Phase 2 MASH/fibrosis RCT published in the New England Journal of Medicine.
- 2024 (Oct)FDA Breakthrough Therapy designation for noncirrhotic MASH (F2-F3); Phase 3 LIVERAGE / LIVERAGE-Cirrhosis initiated.
- 2025 (Nov)Phase 3 SYNCHRONIZE-1 obesity topline: 16.6% weight loss at 76 weeks.
- 2026 (Jun)Phase 3 SYNCHRONIZE-MASLD results published in Nature Medicine; still not FDA-approved.
Verification
The COA standard, applied
Cross-checked across Boehringer Ingelheim releases, peer-reviewed primary literature (NEJM June 2024 for MASH; Lancet Diabetes & Endocrinology 2024 for obesity; Nature Medicine June 2026 for SYNCHRONIZE-MASLD), ClinicalTrials.gov registrations (NCT06066515, NCT06632444, NCT06077864, NCT04771273), and secondary medical news (AJMC, HCPLive, Healio, Pharmacy Times). PubMed citation URLs returned a bot-check page on automated fetch but are well-formed and resolve in a normal browser; cited search terms map to confirmed indexed papers. Grey-market absence corroborated by peptide-vendor landscape coverage (Chainalysis, The Hill) where survodutide is conspicuously absent vs retatrutide.
The full verification standard →Sources
Where this comes from
- Phase 2 MASH RCT - New England Journal of Medicine (June 2024) ↗· Pivotal Phase 2 biopsy-endpoint trial; MASH improvement 47-62% (survodutide) vs 14% placebo at 48 weeks. Primary peer-reviewed evidence.
- PubMed - survodutide MASH randomized phase 2 ↗· PubMed index of the NEJM MASH trial and related records (search-term URL).
- PubMed - survodutide obesity phase 2 ↗· Indexes the Lancet Diabetes & Endocrinology 2024 obesity dose-finding RCT (~19% weight loss at 46 weeks).
- PubMed - survodutide pharmacokinetics half-life ↗· PK/tolerability literature; supports ~109-115 h half-life, >99% albumin binding, once-weekly dosing, steady state ~week 5.
- ClinicalTrials.gov - SYNCHRONIZE-1 Phase 3 obesity (NCT06066515) ↗· Phase 3 obesity RCT; topline 16.6% weight loss at 76 weeks (Nov 2025).
- ClinicalTrials.gov - LIVERAGE Phase 3 MASH (NCT06632444) ↗· Pivotal Phase 3 MASH/fibrosis program following Breakthrough Therapy designation; confirms drug is still investigational.
- ClinicalTrials.gov - SYNCHRONIZE-CVOT cardiovascular safety (NCT06077864) ↗· Cardiovascular outcomes trial - relevant to the glucagon-arm heart-rate/CV unknowns.
- Boehringer Ingelheim - survodutide pipeline & Phase 3 announcements ↗· Developer source: FDA Breakthrough Therapy designation (Oct 2024), Phase 3 SYNCHRONIZE/LIVERAGE status. Sponsor - treat as promotional.
- Nature Medicine - SYNCHRONIZE-MASLD Phase 3 (June 2026) ↗· Most recent Phase 3 peer-reviewed readout in obesity + MASLD.
- The Hill - inside the gray-market peptide world ↗· Context for community-signal lens: maps which peptides are grey-market-available; survodutide is notably not a featured grey-market compound vs retatrutide.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.